BioCentury’s finance roundup reports a significant market gain for Insilico following its Hong Kong listing. The coverage details the capital infusion and market valuation shifts that followed the listing, and highlights financing moves across radiopharma and AI‑driven drug discovery spaces. The report places Insilico’s performance in the context of broader biotech financing—documenting investor appetite for computational drug‑discovery platforms and the secondary effects on companies planning IPOs on US exchanges. The piece flags radiopharma Aktis and other small‑cap moves as part of the same financing wave.